

Emcure Pharmaceuticals to Acquire Remaining Stake in its Subsidiary Zuventus Healthcare Ltd.

- Board approves acquisition of 20.42% minority stake
- Zuventus to become 100% subsidiary of Emcure post the transaction

Pune, June 21, 2025: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced that its Board of Directors has approved to enter into agreement with minority shareholders of Zuventus Healthcare Ltd., one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure. The transaction is expected to close in Q2 FY 2026.

The domestic market remains a strategic priority for Emcure. This transaction will enable full financial consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its domestic business and unlock synergies.

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com